{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:49:01Z","timestamp":1795009741741,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Selected patients with peritoneal metastases of colorectal cancer (PM-CRC) can benefit from potentially curative cytoreductive surgery (CRS)\u00a0\u00b1\u00a0hyperthermic intraperitoneal chemotherapy (HIPEC), with a median overall survival (OS) of more than 40\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aims of this evidence-based consensus were to define the indications for HIPEC, to select the preferred HIPEC regimens, and to define research priorities regarding the use of HIPEC for PM-CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The consensus steering committee elaborated and formulated pertinent clinical questions according to the PICO (patient, intervention, comparator, outcome) method and assessed the evidence according to the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) framework. Standardized evidence tables were presented to an international expert panel to reach a consensus (4-point, weak and strong positive\/negative) on HIPEC regimens and research priorities through a two-round Delphi process. The consensus was defined as \u2265\u00a050% agreement for the 4-point consensus grading or \u2265\u00a070% for either of the two combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Evidence was weak or very weak for 9\/10 clinical questions. In total, 70\/90 eligible panelists replied to both Delphi rounds (78%), with a consensus for 10\/10 questions on HIPEC regimens. There was strong negative consensus concerning the short duration, high-dose oxaliplatin (OX) protocol (55.7%), and a weak positive vote (53.8\u201364.3%) in favor of mitomycin-C (MMC)-based HIPEC (preferred choice: Dutch protocol: 35\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 90\u00a0min, three fractions), both for primary cytoreduction and recurrence. Determining the role of HIPEC after CRS was considered the most important research question, regarded as essential by 85.7% of the panelists. Furthermore, over 90% of experts suggest performing HIPEC after primary and secondary CRS for recurrence &gt;\u00a01 year after the index surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the available evidence, despite the negative results of PRODIGE 7, HIPEC could be conditionally recommended to patients with PM-CRC after CRS. While more preclinical and clinical data are eagerly awaited to harmonize the procedure further, the MMC-based Dutch protocol remains the preferred regimen after primary and secondary CRS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-023-14368-5","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T13:02:58Z","timestamp":1699448578000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer"],"prefix":"10.1245","volume":"31","author":[{"given":"Martin","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"van Der Speeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"issue":"1","key":"14368_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primer. 2021;7(1):91. https:\/\/doi.org\/10.1038\/s41572-021-00326-6.","journal-title":"Nat Rev Dis Primer."},{"issue":"12","key":"14368_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/DCR.0b013e3182a62d9d","volume":"56","author":"I Thomassen","year":"2013","unstructured":"Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56(12):1373\u201380. https:\/\/doi.org\/10.1097\/DCR.0b013e3182a62d9d.","journal-title":"Dis Colon Rectum."},{"issue":"8","key":"14368_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YRBM van Gestel","year":"2014","unstructured":"van Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"14368_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"issue":"6","key":"14368_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamaoncol.2015.1790","volume":"1","author":"I Jawed","year":"2015","unstructured":"Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis. JAMA Oncol. 2015;1(6):787\u201395. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1790.","journal-title":"JAMA Oncol."},{"issue":"11","key":"14368_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, Bhatt A, P\u00e9ron J, et al. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol. 2022;19(11):698\u2013718. https:\/\/doi.org\/10.1038\/s41571-022-00675-5.","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"14368_CR7","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1038\/s41467-022-32198-z","volume":"13","author":"KJ Lenos","year":"2022","unstructured":"Lenos KJ, Bach S, Ferreira Moreno L, et al. Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nat Commun. 2022;13(1):4443. https:\/\/doi.org\/10.1038\/s41467-022-32198-z.","journal-title":"Nat Commun."},{"issue":"8","key":"14368_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/jnci\/djab001","volume":"113","author":"E Breuer","year":"2021","unstructured":"Breuer E, Hebeisen M, Schneider MA, et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst. 2021;113(8):1027\u201335. https:\/\/doi.org\/10.1093\/jnci\/djab001.","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"14368_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"12","key":"14368_CR10","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","volume":"46","author":"M H\u00fcbner","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS\u00ae) society recommendations\u2014part I: preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292\u2013310. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.041.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"14368_CR11","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ejso.2020.08.006","volume":"46","author":"M H\u00fcbner","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS\u00ae) society recommendations\u2014part II: postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311\u201323. https:\/\/doi.org\/10.1016\/j.ejso.2020.08.006.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"14368_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Goere","year":"2020","unstructured":"Goere D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30322-3.","journal-title":"Lancet Oncol."},{"issue":"4 Suppl","key":"14368_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2019.37.4_suppl.482","volume":"37","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: primary outcome of the COLOPEC multicenter randomized trial. J Clin Oncol. 2019;37(4 Suppl):482. https:\/\/doi.org\/10.1200\/JCO.2019.37.4_suppl.482.","journal-title":"J Clin Oncol."},{"issue":"5","key":"14368_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jviscsurg.2019.08.002","volume":"156","author":"K Abboud","year":"2019","unstructured":"Abboud K, Andr\u00e9 T, Brunel M, et al. Management of colorectal peritoneal metastases: expert opinion. J Visc Surg. 2019;156(5):377\u20139. https:\/\/doi.org\/10.1016\/j.jviscsurg.2019.08.002.","journal-title":"J Visc Surg."},{"issue":"2","key":"14368_CR15","doi-asserted-by":"publisher","first-page":"20190006","DOI":"10.1515\/pp-2019-0006","volume":"4","author":"A Pinto","year":"2019","unstructured":"Pinto A, Pocard M. Hyperthermic intraperitoneal chemotherapy with cisplatin and mitomycin C for colorectal cancer peritoneal metastases: a systematic review of the literature. Pleura Peritoneum. 2019;4(2):20190006. https:\/\/doi.org\/10.1515\/pp-2019-0006.","journal-title":"Pleura Peritoneum."},{"issue":"10","key":"14368_CR16","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00384-020-03702-y","volume":"35","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wu Q, Wei M, Deng X, Gu C, Wang Z. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis. 2020;35(10):1831\u20139. https:\/\/doi.org\/10.1007\/s00384-020-03702-y.","journal-title":"Int J Colorectal Dis."},{"issue":"11","key":"14368_CR17","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","volume":"47","author":"VCJ van de Vlasakker","year":"2021","unstructured":"van de Vlasakker VCJ, Lurvink RJ, Cashin PH, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47(11):2888\u201392. https:\/\/doi.org\/10.1016\/j.ejso.2021.05.023.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"14368_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/jcm7120567","volume":"7","author":"C Yurttas","year":"2018","unstructured":"Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7(12):567. https:\/\/doi.org\/10.3390\/jcm7120567.","journal-title":"J Clin Med."},{"issue":"13","key":"14368_CR19","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1245\/s10434-021-10205-9","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, Van Der Speeten K, Hubner M, Kusamura S, Glehen O. ASO Author Reflections: standardizing HIPEC methodology and regimens: a prelude to the PSOGI expert consensus. Ann Surg Oncol. 2021;28(13):9114\u20135. https:\/\/doi.org\/10.1245\/s10434-021-10205-9.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14368_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejso.2019.03.012","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Villeneuve L, Govaerts K, et al. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. 2021;47(1):4\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.012.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"14368_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without Mitomycin C-based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol. 2020;27(1):98\u2013106. https:\/\/doi.org\/10.1245\/s10434-019-07935-2.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"14368_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10147-012-0397-5","volume":"18","author":"TC Chua","year":"2013","unstructured":"Chua TC, Liauw W, Zhao J, Morris DL. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013;18(3):439\u201346. https:\/\/doi.org\/10.1007\/s10147-012-0397-5.","journal-title":"Int J Clin Oncol."},{"issue":"9","key":"14368_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108509","volume":"9","author":"CQ Huang","year":"2014","unstructured":"Huang CQ, Yang XJ, Yu Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. PloS One. 2014;9(9):e108509. https:\/\/doi.org\/10.1371\/journal.pone.0108509.","journal-title":"PloS One."},{"issue":"2","key":"14368_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Quenet","year":"2011","unstructured":"Quenet F, Go\u00e9r\u00e9 D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254(2):294\u2013301. https:\/\/doi.org\/10.1097\/SLA.0b013e3182263933.","journal-title":"Ann Surg."},{"issue":"7","key":"14368_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779\u201385. https:\/\/doi.org\/10.1002\/jso.23728.","journal-title":"J Surg Oncol."},{"issue":"10PtA","key":"14368_CR26","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","volume":"46","author":"C Bakkers","year":"2020","unstructured":"Bakkers C, van Erning FN, Rovers KP, et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. Eur J Surg Oncol. 2020;46(10PtA):1902\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2020.04.018.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"14368_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4251\/wjgo.v12.i8.903","volume":"12","author":"J Spiegelberg","year":"2020","unstructured":"Spiegelberg J, Neeff H, Holzner P, Runkel M, Fichtner-Feigl S, Glatz T. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer. World J Gastrointest Oncol. 2020;12(8):903\u201317. https:\/\/doi.org\/10.4251\/wjgo.v12.i8.903.","journal-title":"World J Gastrointest Oncol."},{"issue":"8","key":"14368_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/jso.25920","volume":"121","author":"MR Woeste","year":"2020","unstructured":"Woeste MR, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol. 2020;121(8):1298\u2013305. https:\/\/doi.org\/10.1002\/jso.25920.","journal-title":"J Surg Oncol."},{"issue":"2","key":"14368_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bjs5.50250","volume":"4","author":"FMK Elekonawo","year":"2020","unstructured":"Elekonawo FMK, van Eden WJ, van der Plas WY, et al. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. BJS Open. 2020;4(2):293\u2013300. https:\/\/doi.org\/10.1002\/bjs5.50250.","journal-title":"BJS Open."},{"issue":"6","key":"14368_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","volume":"109","author":"D Hompes","year":"2014","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, et al. The use of oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109(6):527\u201332. https:\/\/doi.org\/10.1002\/jso.23546.","journal-title":"J Surg Oncol."},{"issue":"1","key":"14368_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","volume":"43","author":"V Leung","year":"2017","unstructured":"Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.015.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"14368_CR32","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s11605-019-04447-y","volume":"24","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan V, Warrier S, Michael M, Ramsay R, Heriot A. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. J Gastrointest Surg. 2020;24(9):2104\u201312. https:\/\/doi.org\/10.1007\/s11605-019-04447-y.","journal-title":"J Gastrointest Surg."},{"issue":"3","key":"14368_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/00015458.2006.11679897","volume":"106","author":"A Rouers","year":"2006","unstructured":"Rouers A, Laurent S, Detroz B, Meurisse M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C. Acta Chir Belg. 2006;106(3):302\u20136. https:\/\/doi.org\/10.1080\/00015458.2006.11679897.","journal-title":"Acta Chir Belg."},{"issue":"2","key":"14368_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ van Eden","year":"2018","unstructured":"van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44(2):220\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2017.10.216.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"14368_CR35","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1245\/s10434-021-09684-7","volume":"28","author":"S Laks","year":"2021","unstructured":"Laks S, Schtrechman G, Adileh M, et al. Repeat cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer peritoneal recurrences is safe and efficacious. Ann Surg Oncol. 2021;28(9):5330\u20138. https:\/\/doi.org\/10.1245\/s10434-021-09684-7.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"14368_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jso.23228","volume":"107","author":"G Glockzin","year":"2013","unstructured":"Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013;107(6):574\u20138. https:\/\/doi.org\/10.1002\/jso.23228.","journal-title":"J Surg Oncol."},{"key":"14368_CR37","doi-asserted-by":"publisher","first-page":"1920276","DOI":"10.1155\/2018\/1920276","volume":"2018","author":"A Sipok","year":"2018","unstructured":"Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Gushchin V. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276. https:\/\/doi.org\/10.1155\/2018\/1920276.","journal-title":"Int J Surg Oncol."},{"issue":"10","key":"14368_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"5","key":"14368_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/02656736.2017.1306119","volume":"33","author":"C Honor\u00e9","year":"2017","unstructured":"Honor\u00e9 C, Gelli M, Francoual J, Benhaim L, Elias D, Go\u00e9r\u00e9 D. Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperth. 2017;33(5):505\u201310. https:\/\/doi.org\/10.1080\/02656736.2017.1306119.","journal-title":"Int J Hyperth."},{"issue":"1","key":"14368_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","volume":"20","author":"C Honor\u00e9","year":"2013","unstructured":"Honor\u00e9 C, Go\u00e9r\u00e9 D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20(1):183\u201392. https:\/\/doi.org\/10.1245\/s10434-012-2473-5.","journal-title":"Ann Surg Oncol."},{"key":"14368_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ijscr.2020.09.017","volume":"75","author":"PH Sugarbaker","year":"2020","unstructured":"Sugarbaker PH, Stuart OA. Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients. Int J Surg Case Rep. 2020;75:279\u201385. https:\/\/doi.org\/10.1016\/j.ijscr.2020.09.017.","journal-title":"Int J Surg Case Rep."},{"issue":"4","key":"14368_CR42","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/SLA.0b013e31826b4dcc","volume":"256","author":"A Andreou","year":"2012","unstructured":"Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256(4):642\u201350. https:\/\/doi.org\/10.1097\/SLA.0b013e31826b4dcc.","journal-title":"Ann Surg."},{"issue":"4","key":"14368_CR43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ejso.2020.09.017","volume":"47","author":"RA Nagourney","year":"2021","unstructured":"Nagourney RA, Evans S, Tran PH, Nagourney AJ, Sugarbaker PH. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg Oncol. 2021;47(4):738\u201342. https:\/\/doi.org\/10.1016\/j.ejso.2020.09.017.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"14368_CR44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275\u201392. https:\/\/doi.org\/10.1002\/path.1706.","journal-title":"J Pathol."},{"issue":"15","key":"14368_CR45","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.3390\/ijms20153619","volume":"20","author":"P Noordhuis","year":"2019","unstructured":"Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ. Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines. Int J Mol Sci. 2019;20(15):3619. https:\/\/doi.org\/10.3390\/ijms20153619.","journal-title":"Int J Mol Sci."},{"key":"14368_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/1471-2164-14-480","volume":"14","author":"P Virag","year":"2013","unstructured":"Virag P, Fischer-Fodor E, Perde-Schrepler M, et al. Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genom. 2013;14:480. https:\/\/doi.org\/10.1186\/1471-2164-14-480.","journal-title":"BMC Genom"},{"issue":"14","key":"14368_CR47","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.18632\/oncotarget.26667","volume":"10","author":"L Lemoine","year":"2019","unstructured":"Lemoine L, Thijssen E, Carleer R, et al. Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. Oncotarget. 2019;10(14):1407\u201324. https:\/\/doi.org\/10.18632\/oncotarget.26667.","journal-title":"Oncotarget."},{"issue":"1","key":"14368_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-010-1460-4","volume":"68","author":"K Van der Speeten","year":"2011","unstructured":"Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;68(1):147\u201356. https:\/\/doi.org\/10.1007\/s00280-010-1460-4.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"8","key":"14368_CR49","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO.1998.16.8.2739","volume":"16","author":"Y B\u00e9couarn","year":"1998","unstructured":"B\u00e9couarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998;16(8):2739\u201344. https:\/\/doi.org\/10.1200\/JCO.1998.16.8.2739.","journal-title":"J Clin Oncol."},{"issue":"16","key":"14368_CR50","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938\u201347. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938.","journal-title":"J Clin Oncol."},{"issue":"23","key":"14368_CR51","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709.","journal-title":"N Engl J Med."},{"issue":"19","key":"14368_CR52","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109\u201316. https:\/\/doi.org\/10.1200\/JCO.2008.20.6771.","journal-title":"J Clin Oncol."},{"issue":"6","key":"14368_CR53","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bjc.6604955","volume":"100","author":"V Catalano","year":"2009","unstructured":"Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and\/or irinotecan-based chemotherapy. Br J Cancer. 2009;100(6):881\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6604955.","journal-title":"Br J Cancer."},{"issue":"3","key":"14368_CR54","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45(3):400\u20132. https:\/\/doi.org\/10.1016\/j.ejso.2018.10.542.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"14368_CR55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt591.","journal-title":"Ann Oncol."},{"issue":"3","key":"14368_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/PPO.0b013e3181a58d7c","volume":"15","author":"VJ Verwaal","year":"2009","unstructured":"Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J. 2009;15(3):212\u20135. https:\/\/doi.org\/10.1097\/PPO.0b013e3181a58d7c.","journal-title":"Cancer J."},{"issue":"9","key":"14368_CR57","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol."},{"issue":"20","key":"14368_CR58","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187.","journal-title":"J Clin Oncol."},{"issue":"4","key":"14368_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jso.21059","volume":"98","author":"S Kusamura","year":"2008","unstructured":"Kusamura S, Baratti D, Younan R, Deraco M. The Delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol. 2008;98(4):217\u20139. https:\/\/doi.org\/10.1002\/jso.21059.","journal-title":"J Surg Oncol."},{"issue":"1","key":"14368_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CAD.0b013e3282f07791","volume":"19","author":"MN Kirstein","year":"2008","unstructured":"Kirstein MN, Root SA, Moore MM, et al. Exposure\u2013response relationships for oxaliplatin-treated colon cancer cells. Anticancer Drugs. 2008;19(1):37\u201344. https:\/\/doi.org\/10.1097\/CAD.0b013e3282f07791.","journal-title":"Anticancer Drugs."},{"issue":"7","key":"14368_CR61","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","volume":"23","author":"T Charrier","year":"2016","unstructured":"Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23(7):2315\u201322. https:\/\/doi.org\/10.1245\/s10434-016-5143-1.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"14368_CR62","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ejso.2017.01.015","volume":"43","author":"JB Delhorme","year":"2017","unstructured":"Delhorme JB, Sattler L, Severac F, et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor? Eur J Surg Oncol. 2017;43(6):1095\u2013101. https:\/\/doi.org\/10.1016\/j.ejso.2017.01.015.","journal-title":"Eur J Surg Oncol."},{"issue":"4PtA","key":"14368_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ejso.2019.10.032","volume":"46","author":"SP Somashekhar","year":"2020","unstructured":"Somashekhar SP, Yethadka R, Kumar CR, Ashwin KR, Zaveri S, Rauthan A. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Eur J Surg Oncol. 2020;46(4PtA):577\u201381. https:\/\/doi.org\/10.1016\/j.ejso.2019.10.032.","journal-title":"Eur J Surg Oncol."},{"issue":"Suppl 1","key":"14368_CR64","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.21037\/jgo-2020-05","volume":"12","author":"P Cashin","year":"2021","unstructured":"Cashin P, Sugarbaker PH. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol. 2021;12(Suppl 1):S120\u20138. https:\/\/doi.org\/10.21037\/jgo-2020-05.","journal-title":"J Gastrointest Oncol."},{"issue":"Suppl 1","key":"14368_CR65","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.21037\/jgo-2020-15","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Van der Speeten K. The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol. 2021;12(Suppl 1):S129\u201330. https:\/\/doi.org\/10.21037\/jgo-2020-15.","journal-title":"J Gastrointest Oncol."},{"issue":"5","key":"14368_CR66","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/cancers14051158","volume":"14","author":"N Seyfried","year":"2022","unstructured":"Seyfried N, Yurttas C, Burkard M, et al. Prolonged exposure to oxaliplatin during HIPEC improves effectiveness in a preclinical micrometastasis model. Cancers. 2022;14(5):1158. https:\/\/doi.org\/10.3390\/cancers14051158.","journal-title":"Cancers."},{"issue":"6","key":"14368_CR67","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1245\/s10434-022-11429-z","volume":"29","author":"KI Votanopoulos","year":"2022","unstructured":"Votanopoulos KI. Repeat CRS\/HIPEC: it comes down to tumor biology and ability to achieve a complete CRS. Ann Surg Oncol. 2022;29(6):3366\u20138. https:\/\/doi.org\/10.1245\/s10434-022-11429-z.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"14368_CR68","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2217\/fon-2016-0389","volume":"13","author":"M Gelli","year":"2017","unstructured":"Gelli M, Huguenin JF, Cerebelli C, et al. Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. Future Oncol. 2017;13(10):907\u201318. https:\/\/doi.org\/10.2217\/fon-2016-0389.","journal-title":"Future Oncol."},{"issue":"1","key":"14368_CR69","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens GAAM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II\u2013III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19(1):390. https:\/\/doi.org\/10.1186\/s12885-019-5545-0.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14368-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T16:42:00Z","timestamp":1701708120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14368-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["14368"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14368-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}